MBC is a rare disease, which has different clinicopathological and immunohistochemical features from FBC.^1–4 According to the latest data from the American Cancer Society, it accounts for about 0.98% and 1.18% of breast cancer morbidity and mortality, respectively.⁵ The incidence of MBC has increased by 20–25% in the past few decades and continues to rise,^6,7 and even reached 15% in some specific populations.⁸ The prognosis of MBC is worse than that of female patients due to older age and advanced stage at diagnosis.^9–11 Distant metastasis is an important factor influencing the prognosis of breast cancer. Nearly 20–30% of breast cancer patients with early age will finally develop metastatic lesions after diagnosis,^12,13 and 90% of breast cancer deaths are caused by metastasis leading to resistance to treatment.¹⁴ Two previous studies based on the Surveillance, Epidemiology and End results (SEER) database have shown that stage IV accounts for about 7–9% of all MBC patients.^15–17 Because distant solid organ metastasis data in the SEER database was collected from 2010, previous studies were unable to study the specific metastasis sites of stage IV MBC patients.

中文翻译：

---

美国男性乳腺癌患者的转移模式和预后：来自 SEER 数据库的基于人群的研究

MBC是一种罕见病，具有与FBC不同的临床病理和免疫组化特征。^1-4根据美国癌症协会的最新数据，它分别占乳腺癌发病率和死亡率的 0.98% 和 1.18%。⁵ MBC 的发病率在过去几十年中增加了 20-25%，并且还在继续上升，在某些特定人群中高达^6.7 %，甚至达到 15%。⁸ MBC 的预后比女性患者更差，因为年龄较大且诊断时处于晚期。^9-11远处转移是影响乳腺癌预后的重要因素。近 20-30% 的早期乳腺癌患者在确诊后最终会发展为转移性病变，^12,13和 90% 的乳腺癌死亡是由于转移导致对治疗产生耐药性。¹⁴基于监测、流行病学和最终结果 (SEER) 数据库的两项先前研究表明，IV 期约占所有 MBC 患者的 7-9%。^15-17由于 SEER 数据库中的远处实体器官转移数据是从 2010 年收集的，以前的研究无法研究 IV 期 MBC 患者的特定转移部位。